|
1
|
Tran LS, Chia J, Le Guezennec X, Tham KM,
Nguyen AT, Sandrin V, Chen WC, Leng TT, Sechachalam S, Leong KP and
Bard FA: ER O-glycosylation in synovial fibroblasts drives
cartilage degradation. Nat Commun. 16(2535)2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mereiter S, Balmaña M, Campos D, Gomes J
and Reis CA: Glycosylation in the era of cancer-targeted therapy:
Where are we heading? Cancer Cell. 36:6–16. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
RodrÍguez E, Schetters STT and van Kooyk
Y: The tumour glyco-code as a novel immune checkpoint for
immunotherapy. Nat Rev Immunol. 18:204–211. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kato K, Jeanneau C, Tarp MA, Benet-Pagès
A, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM and Clausen
H: Polypeptide GalNAc-transferase T3 and familial tumoral
calcinosis. Secretion of fibroblast growth factor 23 requires
O-glycosylation. J Biol Chem. 281:18370–18377. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Miao C, Sun R, Ji D, Wu M, Fu Q, Mei L and
Wu Z: Mechanism of the GALNT family proteins in regulating
tumorigenesis and development of lung cancer (Review). Mol Clin
Oncol. 22(37)2025.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kato K, Hansen L and Clausen H:
Polypeptide N-acetylgalactosaminyltransferase-associated phenotypes
in mammals. Molecules. 26(2204)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bennett EP, Weghuis DO, Merkx G, van
Kessel AG, Eiberg H and Clausen H: Genomic organization and
chromosomal localization of three members of the
UDP-N-acetylgalactosamine: Polypeptide
N-acetylgalactosaminyltransferase family. Glycobiology. 8:547–555.
1998.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fang Y, Chung SSW, Xu L, Xue C, Liu X,
Jiang D, Li R, Korogi Y, Yuan K, Saqi A, et al: RUNX2 promotes
fibrosis via an alveolar-to-pathological fibroblast transition.
Nature. 640:221–230. 2025.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Huang Z, Liu B, Li X, Jin C, Hu Q, Zhao Z,
Sun Y and Wang Q: RUNX2 enhances bladder cancer progression by
promoting glutamine metabolism. Neoplasia.
60(101120)2025.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Huang J, Jia R and Guo J: RUNX2 isoform II
protects cancer cells from ferroptosis and apoptosis by promoting
PRDX2 expression in oral squamous cell carcinoma. Elife.
13(RP99122)2025.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Jiang Q, Qin X, Moriishi T, Fukuyama R,
Katsumata S, Matsuzaki H, Komori H, Matsuo Y, Sakane C, Ito K, et
al: Runx2 regulates Galnt3 and Fgf23 expressions and Galnt3
decelerates osteoid mineralization by stabilizing Fgf23. Int J Mol
Sci. 25(2275)2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Takashi Y and Fukumoto S:
Phosphate-sensing. Adv Exp Med Biol. 1362:27–35. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Takashi Y, Kosako H, Sawatsubashi S,
Kinoshita Y, Ito N, Tsoumpra MK, Nangaku M, Abe M, Matsuhisa M,
Kato S, et al: Activation of unliganded FGF receptor by
extracellular phosphate potentiates proteolytic protection of FGF23
by its O-glycosylation. Proc Natl Acad Sci USA. 116:11418–11427.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Raghu D, Mobley RJ, Shendy NAM, Perry CH
and Abell AN: GALNT3 maintains the epithelial state in trophoblast
stem cells. Cell Rep. 26:3684–3697.e7. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Cheng D, Chu F, Liang F, Zhang N, Wang J
and Yue W: Downregulation of circ-RAPGEF5 inhibits colorectal
cancer progression by reducing the expression of polypeptide
N-acetylgalactosaminyltransferase 3 GALNT3). Environ Toxicol.
39:4249–4260. 2024.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mao W, Zhang L, Wang Y, Sun S, Wu J, Sun
J, Zou X, Chen M and Zhang G: Cisplatin induces acute kidney injury
by downregulating miR-30e-5p that targets Galnt3 to activate the
AMPK signaling pathway. Environ Toxicol. 39:1567–1580.
2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Xu Z, Jin H, Duan X, Liu H, Zhao X, Fan S,
Wang Y and Yao T: LncRNA PSMA3-AS1 promotes cell proliferation,
migration, and invasion in ovarian cancer by activating the
PI3K/Akt pathway via the miR-378a-3p/GALNT3 axis. Environ Toxicol.
36:2562–2577. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lixin S, Wei S, Haibin S, Qingfu L and
Tiemin P: miR-885-5p inhibits proliferation and metastasis by
targeting IGF2BP1 and GALNT3 in human intrahepatic
cholangiocarcinoma. Mol Carcinog. 59:1371–1381. 2020.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Liu B, Pan S, Xiao Y, Liu Q, Xu J and Jia
L: LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer
progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway.
J Exp Clin Cancer Res. 37(316)2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nakamura S, Horie M, Daidoji T, Honda T,
Yasugi M, Kuno A, Komori T, Okuzaki D, Narimatsu H, Nakaya T and
Tomonaga K: Influenza A virus-induced expression of a GalNAc
transferase, GALNT3, via micrornas is required for enhanced viral
replication. J Virol. 90:1788–1801. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Shu G, Lu X, Pan Y, Cen J, Huang K, Zhou
M, Lu J, Dong J, Han H, Chen W, et al: Exosomal circSPIRE1 mediates
glycosylation of E-cadherin to suppress metastasis of renal cell
carcinoma. Oncogene. 42:1802–1820. 2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
de Las Rivas M, Paul Daniel EJ, Narimatsu
Y, Compañón I, Kato K, Hermosilla P, Thureau A, Ceballos-Laita L,
Coelho H, Bernadó P, et al: Molecular basis for fibroblast growth
factor 23 O-glycosylation by GalNAc-T3. Nat Chem Biol. 16:351–360.
2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ichikawa S, Sorenson AH, Austin AM,
Mackenzie DS, Fritz TA, Moh A, Hui SL and Econs MJ: Ablation of the
Galnt3 gene leads to low-circulating intact fibroblast growth
factor 23 (Fgf23) concentrations and hyperphosphatemia despite
increased Fgf23 expression. Endocrinology. 150:2543–2550.
2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Peluso G, Tian E, Abusleme L, Munemasa T,
Mukaibo T and Ten Hagen KG: Loss of the disease-associated
glycosyltransferase Galnt3 alters Muc10 glycosylation and the
composition of the oral microbiome. J Biol Chem. 295:1411–1425.
2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Yoshida CA, Kawane T, Moriishi T,
Purushothaman A, Miyazaki T, Komori H, Mori M, Qin X, Hashimoto A,
Sugahara K, et al: Overexpression of Galnt3 in chondrocytes
resulted in dwarfism due to the increase of mucin-type O-glycans
and reduction of glycosaminoglycans. J Biol Chem. 289:26584–26596.
2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sheta R, Bachvarova M, Macdonald E, Gobeil
S, Vanderhyden B and Bachvarov D: The polypeptide GALNT6 displays
redundant functions upon suppression of its closest homolog GALNT3
in mediating aberrant O-glycosylation, associated with ovarian
cancer progression. Int J Mol Sci. 20(2264)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang YK, Li SJ, Zhou LL, Li D and Guo LW:
GALNT3 protects against vascular calcification by reducing
oxidative stress and apoptosis of smooth muscle cells. Eur J
Pharmacol. 939(175447)2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Noel M, Zürcher YM, Tulin EKC and Cummings
RD: The importance of N- and O-glycosylation of brain cell surface
glycoproteins. Glycobiology. 35(cwaf054)2025.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Gok F, Chefetz I, Indelman M, Kocaoglu M
and Sprecher E: Newly discovered mutations in the GALNT3 gene
causing autosomal recessive hyperostosis-hyperphosphatemia
syndrome. Acta Orthop. 80:131–134. 2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yancovitch A, Hershkovitz D, Indelman M,
Galloway P, Whiteford M, Sprecher E and Kılıç E: Novel mutations in
GALNT3 causing hyperphosphatemic familial tumoral calcinosis. J
Bone Miner Metab. 29:621–625. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Navarro-González JF, Mora-Fernández C,
Diaz-Tocados JM, Bozic M, Bermúdez-López M, Martín M and
Valdivielso JM: Serum phosphate levels modify the impact of FGF23
levels on hemoglobin in chronic kidney disease. Nutrients.
14(4842)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ichikawa S, Gray AK, Padgett LR, Allen MR,
Clinkenbeard EL, Sarpa NM, White KE and Econs MJ: Genetic rescue of
glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
Endocrinology. 155:3891–3898. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ichikawa S, Baujat G, Seyahi A, Garoufali
AG, Imel EA, Padgett LR, Austin AM, Sorenson AH, Pejin Z,
Topouchian V, et al: Clinical variability of familial tumoral
calcinosis caused by novel GALNT3 mutations. Am J Med Genet A.
152A:896–903. 2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ramnitz MS, Gafni RI and Collins MT:
Hyperphosphatemic familial tumoral calcinosis. In:
GeneReviews®. Adam MP, Bick S, Mirzaa GM, Pagon RA,
Wallace SE and Amemiya A (eds). University of Washington, Seattle,
WA, 1993.
|
|
35
|
Guo L, Li D, Li M, Li L and Huang Y:
Variant in GALNT3 gene linked with reduced coronary artery disease
risk in Chinese population. DNA Cell Biol. 36:529–534.
2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Guo L, Wang L, Li H, Yang X, Yang B, Li M,
Huang J and Gu D: Down regulation of GALNT3 contributes to
endothelial cell injury via activation of p38 MAPK signaling
pathway. Atherosclerosis. 245:94–100. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wang B, Zhang Y, Jiang W, Zhu L, Li K,
Zhou K, Dai D, Chang S and Fang M: GALNT3 inhibits NF-κB signaling
during influenza A virus infection. Biochem Biophys Res Commun.
503:2872–2877. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Park MS, Yang AY, Lee JE, Kim SK, Roe JS,
Park MS, Oh MJ, An HJ and Kim MY: GALNT3 suppresses lung cancer by
inhibiting myeloid-derived suppressor cell infiltration and
angiogenesis in a TNFR and c-MET pathway-dependent manner. Cancer
Lett. 521:294–307. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Dosaka-Akita H, Kinoshita I, Yamazaki K,
Izumi H, Itoh T, Katoh H, Nishimura M, Matsuo K, Yamada Y and Kohno
K: N-acetylgalactosaminyl transferase-3 is a potential new marker
for non-small cell lung cancers. Br J Cancer. 87:751–755.
2002.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Gu C, Oyama T, Osaki T, Li J, Takenoyama
M, Izumi H, Sugio K, Kohno K and Yasumoto K: Low expression of
polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung
adenocarcinoma: Impact on poor prognosis and early recurrence. Br J
Cancer. 90:436–442. 2004.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zhao S, Guo T, Li J, Uramoto H, Guan H,
Deng W and Gu C: Expression and prognostic value of GalNAc-T3 in
patients with completely resected small (≤2 cm) peripheral lung
adenocarcinoma after IASLC/ATS/ERS classification. Onco Targets
Ther. 8:3143–3152. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Cavallo F, Astolfi A, Iezzi M, Cordero F,
Lollini PL, Forni G and Calogero R: An integrated approach of
immunogenomics and bioinformatics to identify new tumor associated
antigens (TAA) for mammary cancer immunological prevention. BMC
Bioinformatics. 6 (Suppl 4)(S7)2005.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Taniuchi K, Cerny RL, Tanouchi A, Kohno K,
Kotani N, Honke K, Saibara T and Hollingsworth MA: Overexpression
of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell
growth. Oncogene. 30:4843–4854. 2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Chugh S, Meza J, Sheinin YM, Ponnusamy MP
and Batra SK: Loss of N-acetylgalactosaminyltransferase 3 in poorly
differentiated pancreatic cancer: Augmented aggressiveness and
aberrant ErbB family glycosylation. Br J Cancer. 114:1376–1386.
2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Barkeer S, Chugh S, Karmakar S, Kaushik G,
Rauth S, Rachagani S, Batra SK and Ponnusamy MP: Novel role of
O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of
pancreatic cancer stem cells. BMC Cancer. 18(1157)2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Ungefroren H and Marquardt JU: Dynamic
allostery: A novel mechanism regulating autocrine and paracrine
TGF-β signalling. Signal Transduct Target Ther.
10(3)2025.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Wang J, Zhang L, Li R, Yang R, Yang F, Yu
F and Zhang J: Gambogic acid restores wild-type-like p53 functions
to induce ferroptosis in mutant p53 cancer cells. Biochem
Pharmacol. 243(117533)2026.PubMed/NCBI View Article : Google Scholar
|
|
48
|
David CJ and Massagué J: Contextual
determinants of TGFβ action in development, immunity and cancer.
Nat Rev Mol Cell Biol. 19:419–435. 2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Okano M, Oshi M, Mukhopadhyay S, Qi Q, Yan
L, Endo I, Ohtake T and Takabe K: Octogenarians' breast cancer is
associated with an unfavorable tumor immune microenvironment and
worse disease-free survival. Cancers (Basel).
13(2933)2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Palmer MJ, Mahajan VS, Trajman LC, Irvine
DJ, Lauffenburger DA and Chen J: Interleukin-7 receptor signaling
network: An integrated systems perspective. Cell Mol Immunol.
5:79–89. 2008.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Mayer BJ, Blinov ML and Loew LM: Molecular
machines or pleiomorphic ensembles: Signaling complexes revisited.
J Biol. 8(81)2009.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Sanz-Martinez I, Pereira S, Merino P,
Corzana F and Hurtado-Guerrero R: Molecular recognition of GalNAc
in mucin-type O-glycosylation. Acc Chem Res. 56:548–560.
2023.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Sonawane AR, Platig J, Fagny M, Chen CY,
Paulson JN, Lopes-Ramos CM, DeMeo DL, Quackenbush J, Glass K and
Kuijjer ML: Understanding tissue-specific gene regulation. Cell
Rep. 21:1077–1088. 2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Verma D, Siddharth S, Yende AS, Wu Q and
Sharma D: LUCAT1-mediated competing endogenous RNA (ceRNA) network
in triple-negative breast cancer. Cells. 13(1918)2024.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Qin L, Liu Y, Li M, Pu X and Guo Y: The
landscape of miRNA-related ceRNA networks for marking different
renal cell carcinoma subtypes. Brief Bioinform. 21:73–84.
2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Li X, Peng C, Liu H, Dong M, Li S, Liang
W, Li X and Bai J: Constructing methylation-driven ceRNA networks
unveil tumor heterogeneity and predict patient prognosis. Hum Mol
Genet. 34:251–264. 2025.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Sørensen DM, Büll C, Madsen TD,
Lira-Navarrete E, Clausen TM, Clark AE, Garretson AF, Karlsson R,
Pijnenborg JFA, Yin X, et al: Identification of global inhibitors
of cellular glycosylation. Nat Commun. 14(948)2023.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Davis ME, Zuckerman JE, Choi CH, Seligson
D, Tolcher A, Alabi CA, Yen Y, Heidel JD and Ribas A: Evidence of
RNAi in humans from systemically administered siRNA via targeted
nanoparticles. Nature. 464:1067–1070. 2010.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Dalpke A and Helm M: RNA mediated
Toll-like receptor stimulation in health and disease. RNA Biol.
9:828–842. 2012.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Heard A, Landmann JH, Hansen AR,
Papadopolou A, Hsu YS, Selli ME, Warrington JM, Lattin J, Chang J,
Ha H, et al: Antigen glycosylation regulates efficacy of CAR T
cells targeting CD19. Nat Commun. 13(3367)2022.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Li J, Sun H, Li W, Zhao N, Guo Z, Chen J
and Yu J: Protein post-translational modifications in CAR-T cells:
Novel strategies to amplify antitumor efficacy via epigenetic and
metabolic circuitry. Crit Rev Oncol Hematol.
216(104968)2025.PubMed/NCBI View Article : Google Scholar
|
![Schematic overview of the
transcriptional and epigenetic regulation of GALNT3. [Arrows denote
regulatory effects: Red for positive (activation) and green for
negative (inhibition)]. GALNT3, polypeptide
N-acetylgalactosaminyltransferase 3; miR-, microRNA; ELAVL1,
embryonic lethal abnormal vision-like 1; Runx2, runt-related
transcription factor 2; Pi, extracellular posphate; Egr1, early
growth response 1; Etv5, ETS variant transcription factor 5;
MAP3K4, mitogen-activated protein kinase kinase kinase 4; HDAC6,
histone deacetylase histone deacetylase 6; H2BK5ac, histone H2B at
lysine 5 acetylation. The figure was generated using FigDraw
(https://www.figdraw.com).](/article_images/br/24/5/br-24-05-02137-g01.jpg)
